Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study

PURPOSE: Little data are available regarding the safety and efficacy of switching to Pasireotide-LAR monotherapy in acromegaly patients with partial resistance to first-generation somatostatin agonists (1gSRL) who require combination treatment with cabergoline or pegvisomant. METHOD: In this monocen...

Descripción completa

Detalles Bibliográficos
Autores principales: Lasolle, Hélène, Ferriere, Amandine, Vasiljevic, Alexandre, Eimer, Sandrine, Nunes, Marie-Laure, Tabarin, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790898/
https://www.ncbi.nlm.nih.gov/pubmed/31518993
http://dx.doi.org/10.1530/EC-19-0332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790898/
https://www.ncbi.nlm.nih.gov/pubmed/31518993
http://dx.doi.org/10.1530/EC-19-0332

Ejemplares similares